Patent intelligence · US
US 10703797
Gene therapy vectors for treatment of Danon disease
Gene therapy vectors for treatment of Danon disease
Patent details — US 10703797
- Jurisdiction
- US
- Status
- granted
- Grant date
- Jul 7, 2020
- Expiration
- Jul 2, 2040
- Applicant
- Rocket Pharmaceuticals, Ltd.
- Claims
- 15
- CPC classes
- A61K, A61K38/00, A61K38/177, A61K48/00
Quick answer
US 10703797 (Gene therapy vectors for treatment of Danon disease) is held by Rocket Pharmaceuticals, Ltd.. Status: granted. Granted Jul 7, 2020. Expires Jul 2, 2040 (14 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Rocket Pharmaceuticals, Ltd.
- Grant date
- Expiration
- Claims
- 15
- CPC classes
- A61K, A61K38/00, A61K38/177, A61K48/00, A61K48/0066, A61P
Frequently asked questions
What is US patent 10703797?
US 10703797 (Gene therapy vectors for treatment of Danon disease) is held by Rocket Pharmaceuticals, Ltd.. Status: granted. Granted Jul 7, 2020. Expires Jul 2, 2040 (14 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 10703797?
Rocket Pharmaceuticals, Ltd. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 1 pharmaceutical patents for this assignee.
When does US 10703797 expire?
Our index shows an expiration date of Jul 2, 2040 (14 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.